Affiliate disclosure

Some of the links on my blog are affiliate links. If you use them to make a purchase I will earn a small commission at no additional cost for you.

Thursday, July 14, 2022

Cancer and IP6

 Looks like IP6 may also have positive effects on prostate cancer (ie in the treatment of)!!!

Check out these excerpts from an article on Connersclinic.com!

    IP6 is a selective agent against cancer cells. Because cancer cells are high in iron content, IP6 directs most of its attention to abnormal cells since IP6 acts as a selective iron chelator. IP6 selectively removes iron from tumors cells (stealing one of its major food sources), which deprives them of their primary growth factor.

    There have been numerous lab dish and animal studies that conclusively prove IP6 cancer treatment is an effective and non-toxic, anti-cancer molecule. But the National Cancer Institute has never seen fit to conduct a human trial even though IP6 made it on a list of promising anti-cancer agents. [Fox CH, Complementary Therapy Med 10: 229—34, 2003]

    IP6 enhances the anti-cancer effects of Adriamycin and Tamoxifen, two commonly used cancer drugs. [Tantivejkul K, Breast Cancer Research Treatment 79: 301—12, 2003] However, it goes ignored by cancer doctors even though it’s known to help chemotherapy!

    Ip6 summary:

  • IP6 inhibits cell proliferation; helps stop cancer growth
  • IP6 inhibits cell progression
  • IP6 inhibits metastasis by interfering with CTC (circulating tumor cell) adhesion, migration, and invasion (it inhibits MMP-9 secretion)
  • IP6 induces apoptosis in many cancer cell lines
  • IP6 inhibits Angiogenesis (new blood vessel growth to cancer) by:
    • Inhibiting growth and differentiation of endothelial cells
    • Inhibits secretion of VEGF (vascular endothelial growth factor)
    • Blocking fibroblast growth factor


Check out the full article here:   IP6 Cancer Treatment - It Works as a Chelator

Be blessed,

Tom


No comments:

Post a Comment

Note: Only a member of this blog may post a comment.